Mason Hunter G, Hu Chih-Hsiang, Cordova Leandro Soto, Hakami Ramin M, Veneziano Remi
School of System Biology, College of Science, George Mason University.
Center for Infectious Disease Research, George Mason University.
bioRxiv. 2025 Jul 11:2025.07.10.662041. doi: 10.1101/2025.07.10.662041.
3D printing has become a prevalent technology in many fields such as manufacturing, architecture, and electronics. This additive manufacturing technique is also widely used for biomedical research and clinical applications to prototype or assemble biomedical devices and tools. 3D printing-based strategies for biocompatible materials offer greater design flexibility, enhanced versatility, and faster results than traditional fabrication techniques, advantages that could be especially beneficial to the development of microfluidic chips. The ability to simply and efficiently produce new chip molds from computer aided design (CAD) models would significantly transform the development process and expand its accessibility by removing the need for more complex and expensive lithography methods. However, with standard processing strategies, the use of 3D printed molds for casting functioning chips is limited by the poor quality of prints achievable with widely available 3D printers. To mitigate this issue and facilitate rapid microfluidic device prototyping, we have developed a simple procedure to print microfluidic molds using a stereolithographic (SLA) printer and produce functional polydimethylsiloxane (PDMS) microfluidic chips with height and width feature dimensions as low as 75 μm. Molds printed using a commercially available liquid photopolymer-based resin and processed using our strategy exhibited high dimensional fidelity to intended designs and significantly reduced average surface roughness (< 3 μm). Here, we describe a streamlined post-print processing workflow for SLA molds and its efficacy in reducing surface roughness while preserving dimensional fidelity and then demonstrate its utility by prototyping and optimizing a microfluidic extracellular vesicle (EV)-exchange platform.
3D打印已成为制造、建筑和电子等许多领域的一项普遍技术。这种增材制造技术也广泛用于生物医学研究和临床应用,以制作生物医学设备和工具的原型或进行组装。与传统制造技术相比,基于3D打印的生物相容性材料策略具有更大的设计灵活性、更强的通用性和更快的成果产出,这些优势对微流控芯片的开发可能特别有益。能够从计算机辅助设计(CAD)模型简单高效地生产新的芯片模具,将显著改变开发过程,并通过消除对更复杂、更昂贵的光刻方法的需求来扩大其可及性。然而,采用标准加工策略时,使用3D打印模具来浇铸功能芯片受到广泛使用的3D打印机所能实现的打印质量较差的限制。为了缓解这个问题并促进快速微流控设备原型制作,我们开发了一种简单的程序,使用立体光刻(SLA)打印机打印微流控模具,并生产高度和宽度特征尺寸低至75μm的功能性聚二甲基硅氧烷(PDMS)微流控芯片。使用市售的基于液体光聚合物的树脂打印并采用我们的策略进行处理的模具,对预期设计表现出高尺寸保真度,并显著降低了平均表面粗糙度(<3μm)。在此,我们描述了一种针对SLA模具的简化后处理工作流程及其在降低表面粗糙度同时保持尺寸保真度方面的功效,然后通过制作微流控细胞外囊泡(EV)交换平台的原型并对其进行优化来展示其效用。